Machine learning models can predict postoperative hyperopic shift in patients with primary angle-closure glaucoma.

It's one of the most common causes of vision loss, and one of the easiest to overlook. Glaucoma symptoms develop so gradually ...

Johnson & Johnson (NYSE:JNJ) today announced the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) as a single agent treatment for adult patients ...

The MarketWatch News Department was not involved in the creation of this content. Data to be shared during an ObesityWeek press conference includes four of seven data presentations supporting CONTRAVE ...

The MarketWatch News Department was not involved in the creation of this content. Program ensures continued access to treatment for patients enrolled in the Federal Employee & Retirees Health Plan ...

RARITAN, N.J., Oct. 16, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), the worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 ...

MILLCREEK — The upper part of Millcreek Canyon is one of the most beautiful spots in Salt Lake County for hikers and bikers, but right now, it's also dangerous. Construction crews are warning visitors ...

Open-angle glaucoma often has no symptoms until vision loss begins, so regular screening is important. You can use eye drops and laser therapy to slow the progression of open-angle glaucoma. Try using ...

100 percent of evaluable patients achieved minimal residual disease (MRD) negativity following induction therapy in updated results from the Phase 2 MajesTEC-5 study "Exploring TECVAYLI, with its ...